Neoadjuvant endocrine treatment of women with breast cancer
Neoadjuvant therapy has four goals in breast cancer: decrease tumor volume to operate tumors that initially were inoperable, increase the number of conservative surgeries, evaluate the chemosensitivity in vivo and analyze the management of micrometastases. Neoadjuvant treatment provides a unique set...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2011-09-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/30 |
| _version_ | 1797964737391099904 |
|---|---|
| author | Julian Iturbe Ariel Zwenger Carlos Vallejo Bernardo Leone Pablo Leone |
| author_facet | Julian Iturbe Ariel Zwenger Carlos Vallejo Bernardo Leone Pablo Leone |
| author_sort | Julian Iturbe |
| collection | DOAJ |
| description | Neoadjuvant therapy has four goals in breast cancer: decrease tumor volume to operate tumors that initially were inoperable, increase the number of conservative surgeries, evaluate the chemosensitivity in vivo and analyze the management of micrometastases. Neoadjuvant treatment provides a unique setting in which we can monitor clinical, pathological, proliferative and molecular responses. Combining different strategies such us surgery, radiation therapy, chemotherapy, and endocrine therapy has contributed substantially to the survival improvement in breast cancer. Thirdgeneration aromatase inhibitors have proven to be superior to tamoxifen in the adjuvant and, more recently, the neoadjuvant treatment of postmenopausal patients. The need to define how to select the patients that will benefit the most from these therapies, the optimal duration of treatment, the bestmethod to evaluate the treatment response, the identification of predictive factors for response, and the superiority of certain endocrine agents over others have been reviewed. We have carried out a critical analysis of the current literature on the utilization of endocrine therapy in the neoadjuvant setting for breast cancer. This review discusses the current evidence regarding primary endocrine therapy and the current opinions on length of treatment and measurement of response prior to surgery. |
| first_indexed | 2024-04-11T01:49:41Z |
| format | Article |
| id | doaj.art-424979f09df54157bd108ede09dd0bf7 |
| institution | Directory Open Access Journal |
| issn | 1970-5557 1970-5565 |
| language | English |
| last_indexed | 2024-04-11T01:49:41Z |
| publishDate | 2011-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Oncology Reviews |
| spelling | doaj.art-424979f09df54157bd108ede09dd0bf72023-01-03T06:58:05ZengFrontiers Media S.A.Oncology Reviews1970-55571970-55652011-09-015310.4081/oncol.2011.15725Neoadjuvant endocrine treatment of women with breast cancerJulian Iturbe0Ariel Zwenger1Carlos Vallejo2Bernardo Leone3Pablo Leone4Grupo Oncologico Cooperativo del Sur (GOCS), NeuquenGrupo Oncologico Cooperativo del Sur (GOCS), NeuquenGrupo Oncologico Cooperativo del Sur (GOCS), NeuquenGrupo Oncologico Cooperativo del Sur (GOCS), NeuquenDepartment of Internal Medicine, University of Miami, Jackson Memorial Hospital,Neoadjuvant therapy has four goals in breast cancer: decrease tumor volume to operate tumors that initially were inoperable, increase the number of conservative surgeries, evaluate the chemosensitivity in vivo and analyze the management of micrometastases. Neoadjuvant treatment provides a unique setting in which we can monitor clinical, pathological, proliferative and molecular responses. Combining different strategies such us surgery, radiation therapy, chemotherapy, and endocrine therapy has contributed substantially to the survival improvement in breast cancer. Thirdgeneration aromatase inhibitors have proven to be superior to tamoxifen in the adjuvant and, more recently, the neoadjuvant treatment of postmenopausal patients. The need to define how to select the patients that will benefit the most from these therapies, the optimal duration of treatment, the bestmethod to evaluate the treatment response, the identification of predictive factors for response, and the superiority of certain endocrine agents over others have been reviewed. We have carried out a critical analysis of the current literature on the utilization of endocrine therapy in the neoadjuvant setting for breast cancer. This review discusses the current evidence regarding primary endocrine therapy and the current opinions on length of treatment and measurement of response prior to surgery.http://www.oncologyreviews.org/index.php/or/article/view/30Breast cancer - Neoadjuvant therapy - Hormone therapy Tamoxifen - Aromatase inhibitors |
| spellingShingle | Julian Iturbe Ariel Zwenger Carlos Vallejo Bernardo Leone Pablo Leone Neoadjuvant endocrine treatment of women with breast cancer Oncology Reviews Breast cancer - Neoadjuvant therapy - Hormone therapy Tamoxifen - Aromatase inhibitors |
| title | Neoadjuvant endocrine treatment of women with breast cancer |
| title_full | Neoadjuvant endocrine treatment of women with breast cancer |
| title_fullStr | Neoadjuvant endocrine treatment of women with breast cancer |
| title_full_unstemmed | Neoadjuvant endocrine treatment of women with breast cancer |
| title_short | Neoadjuvant endocrine treatment of women with breast cancer |
| title_sort | neoadjuvant endocrine treatment of women with breast cancer |
| topic | Breast cancer - Neoadjuvant therapy - Hormone therapy Tamoxifen - Aromatase inhibitors |
| url | http://www.oncologyreviews.org/index.php/or/article/view/30 |
| work_keys_str_mv | AT julianiturbe neoadjuvantendocrinetreatmentofwomenwithbreastcancer AT arielzwenger neoadjuvantendocrinetreatmentofwomenwithbreastcancer AT carlosvallejo neoadjuvantendocrinetreatmentofwomenwithbreastcancer AT bernardoleone neoadjuvantendocrinetreatmentofwomenwithbreastcancer AT pabloleone neoadjuvantendocrinetreatmentofwomenwithbreastcancer |